Exact Sciences Comprehensive Income 2010-2025 | EXAS

Exact Sciences comprehensive income for the quarter ending March 31, 2025 was $0.001B, a 303.01% decline year-over-year.

  • Exact Sciences comprehensive income for 2024 was $-0.001B, a 166.11% decline from 2023.
  • Exact Sciences comprehensive income for 2023 was $0.001B, a 127.27% decline from 2022.
  • Exact Sciences comprehensive income for 2022 was $-0.005B, a 262.86% increase from 2021.

Exact Sciences Comprehensive Income 2010-2025 | EXAS

  • Exact Sciences comprehensive income for 2024 was $-0.001B, a 166.11% decline from 2023.
  • Exact Sciences comprehensive income for 2023 was $0.001B, a 127.27% decline from 2022.
  • Exact Sciences comprehensive income for 2022 was $-0.005B, a 262.86% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$214.8B
Amgen (AMGN)$160.4B
Gilead Sciences (GILD)$135.3B
Vertex Pharmaceuticals (VRTX)$119B
Bristol Myers Squibb (BMY)$97.8B
CSL (CSLLY)$78.3B
GSK (GSK)$74.7B
Regeneron Pharmaceuticals (REGN)$59.4B
Alnylam Pharmaceuticals (ALNY)$42.3B
Argenex SE (ARGX)$35B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$19.9B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.9B
Illumina (ILMN)$15.5B
Genmab (GNMSF)$14.5B
Genmab (GMAB)$14.1B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.5B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
Ascendis Pharma (ASND)$10.8B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Legend Biotech (LEGN)$7.7B
Regencell Bioscience Holdings (RGC)$7.3B